{"disease":{"id":"recurrent-tumor","name":"recurrent tumor"},"drugs":{"marketed":[{"drug_id":"dostarlimab-gxly","indication_name":"Mismatch Repair Deficient Recurrent or Advanced Solid Tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"JEMPERLI","generic_name":"DOSTARLIMAB-GXLY","company_name":"GLAXOSMITHKLINE","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"Programmed Death Receptor-1 Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":"Dostarlimab-gxly blocks PD-1 receptor interaction with PD-L1 and PD-L2, enhancing anti-tumor immune response."},{"drug_id":"bacillus-calmette-guerin","indication_name":"Prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bacillus-calmette-guerin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Mycobacterium tuberculosis","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"larotrectinib","indication_name":"NTRK fusion gene-positive advanced or recurrent solid tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vitrakvi","generic_name":"LAROTRECTINIB","company_name":"Bayer","drug_phase":"marketed","molecular_target":"High affinity nerve growth factor receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":55,"revenue":null,"mechanism":"Vitrakvi works by blocking the activity of a specific protein called the nerve growth factor receptor."}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05793281","title":"An Observational Study to Learn More About NTRK Gene Fusion Positive in Solid Tumor in Japan","phase":"","overall_status":"COMPLETED","enrollment_count":46621,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04596865","title":"Recurrence After Whipple's (RAW) Study","phase":"","overall_status":"COMPLETED","enrollment_count":1484,"lead_sponsor_name":"University Hospital Plymouth NHS Trust","has_results":false},{"nct_id":"NCT03155620","title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1377,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00919750","title":"Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":1258,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT03398915","title":"The European Robotic Spinal Instrumentation (EUROSPIN) Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":932,"lead_sponsor_name":"Marc Schröder","has_results":true},{"nct_id":"NCT00899990","title":"Collecting and Storing Biological Samples From Patients With Ewing Sarcoma","phase":"","overall_status":"COMPLETED","enrollment_count":908,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT04427384","title":"Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"GT Medical Technologies, Inc.","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06330064","title":"A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":520,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT05895214","title":"Mesopancreas Study in Pancreatic Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Heinrich-Heine University, Duesseldorf","has_results":false},{"nct_id":"NCT04907643","title":"Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes","phase":"NA","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT05444478","title":"Microwave Ablation Simultaneously Combined With Lenavatinib for Recurrent Hepatocellular Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":274,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04322318","title":"A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":256,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06031441","title":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT03760952","title":"Human Leukocyte Antigen Typing and Tumor Antigen Expression Profiling","phase":"","overall_status":"COMPLETED","enrollment_count":242,"lead_sponsor_name":"Immatics US, Inc.","has_results":false},{"nct_id":"NCT06273176","title":"The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma","phase":"","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT03330405","title":"Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":223,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT04732065","title":"ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":208,"lead_sponsor_name":"Sabine Mueller, MD, PhD","has_results":false},{"nct_id":"NCT01730950","title":"Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Radiation Therapy Oncology Group","has_results":true},{"nct_id":"NCT00536601","title":"High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors","phase":"NA","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true},{"nct_id":"NCT00749723","title":"Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":174,"lead_sponsor_name":"University Hospital, Bonn","has_results":false},{"nct_id":"NCT01841736","title":"Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":171,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06022029","title":"A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":168,"lead_sponsor_name":"OncoNano Medicine, Inc.","has_results":false},{"nct_id":"NCT02601209","title":"Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":151,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04851119","title":"Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT02304458","title":"Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01286987","title":"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02122185","title":"Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT03750396","title":"Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":110,"lead_sponsor_name":"Gangnam Severance Hospital","has_results":false},{"nct_id":"NCT06262919","title":"Special Drug Use-results Surveillance of Tafinlar/Mekinist","phase":"","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02867592","title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":109,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06609876","title":"Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC","phase":"NA","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01217437","title":"Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04945330","title":"NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT03025893","title":"A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Amsterdam UMC, location VUmc","has_results":false},{"nct_id":"NCT06093698","title":"An Exploratory Study of A-337 in the Management of Malignant Solid Dose Escalation and Expansion Phases","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":94,"lead_sponsor_name":"ITabMed Co., Ltd.","has_results":false},{"nct_id":"NCT04901702","title":"Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT06184035","title":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"Spago Nanomedical AB","has_results":false},{"nct_id":"NCT01814813","title":"Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":90,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":true},{"nct_id":"NCT05286801","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":86,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07374692","title":"Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors","phase":"NA","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05210413","title":"Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":80,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05001282","title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"Elucida Oncology","has_results":false},{"nct_id":"NCT06541639","title":"EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06525246","title":"Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Ono Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07015697","title":"A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT05036226","title":"COAST Therapy in Advanced Solid Tumors and Prostate Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Medical University of South Carolina","has_results":false},{"nct_id":"NCT04962867","title":"NCCH2006/MK010 Trial (FORTUNE Trial)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"National Cancer Center, Japan","has_results":false},{"nct_id":"NCT03657381","title":"Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":75,"lead_sponsor_name":"Shandong New Time Pharmaceutical Co., LTD","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}